Abstract
New therapies based on the targeting of signal pathways (such as VHL/HIF-1) common to most renal cell carcinomas (RCC), have greatly improved the outlook for sufferers of this disease. Given the growing reputation of many microRNAs (miRNAs) as both tumor suppressors and oncogenes, the measurement and manipulation of these small nucleotides in RCC patients may provide yet another valuable advance in renal cancer diagnosis and treatment. The present review summarizes the current literature on the role of microRNAs in RCC development and progression emphasizing the interaction of specific miRNAs with both oncogenic and tumor suppressor pathways of particular importance in renal cancer.
Keywords: c-MET, cancer, hypoxia-inducible factor (HIF), mammalian target of rapamycin (mTOR), miRNA, renal cell carcinoma, vascular endothelial growth factor (VEGF), Von Hippel-Lindau protein (VHL).
Graphical Abstract
MicroRNA
Title:MicroRNAs in Renal Cell Carcinoma
Volume: 4 Issue: 1
Author(s): Donald F. Sellitti and Sonia Q. Doi
Affiliation:
Keywords: c-MET, cancer, hypoxia-inducible factor (HIF), mammalian target of rapamycin (mTOR), miRNA, renal cell carcinoma, vascular endothelial growth factor (VEGF), Von Hippel-Lindau protein (VHL).
Abstract: New therapies based on the targeting of signal pathways (such as VHL/HIF-1) common to most renal cell carcinomas (RCC), have greatly improved the outlook for sufferers of this disease. Given the growing reputation of many microRNAs (miRNAs) as both tumor suppressors and oncogenes, the measurement and manipulation of these small nucleotides in RCC patients may provide yet another valuable advance in renal cancer diagnosis and treatment. The present review summarizes the current literature on the role of microRNAs in RCC development and progression emphasizing the interaction of specific miRNAs with both oncogenic and tumor suppressor pathways of particular importance in renal cancer.
Export Options
About this article
Cite this article as:
Sellitti F. Donald and Doi Q. Sonia, MicroRNAs in Renal Cell Carcinoma, MicroRNA 2015; 4 (1) . https://dx.doi.org/10.2174/2211536604666150713105247
DOI https://dx.doi.org/10.2174/2211536604666150713105247 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sphingolipid Signaling and Hematopoietic Malignancies: To the Rheostat and Beyond
Anti-Cancer Agents in Medicinal Chemistry Epigenetically - Targeted Therapies for the Treatment of Hematological Malignancies
Current Medicinal Chemistry The Beneficial Role of Vitamin D in Human Immunodeficiency Virus Infection
Current HIV Research Vitamin D Receptor: A Novel Therapeutic Target for Kidney Diseases
Current Medicinal Chemistry Current Status and Future Perspectives of Chemoprevention in Head and Neck Cancer
Current Cancer Drug Targets From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Titanium Dioxide Nanoparticles: a Risk for Human Health?
Mini-Reviews in Medicinal Chemistry Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry Imaging of Integrins as Biomarkers for Tumor Angiogenesis
Current Pharmaceutical Design Canonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics
Current Medicinal Chemistry MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential
Current Genomics Recent Developments in the Field of Tumor-Inhibiting Metal Complexes
Current Pharmaceutical Design HPV Cervical Infection and Immunodysregulation: Synergistic Risks for Neoplasia-Review
Current Women`s Health Reviews Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Recent Clinical Aspects of Hyperprolactinemia Induced by Antipsychotics
Reviews on Recent Clinical Trials Targeting Angiogenesis in Renal Cell Carcinoma
Current Cancer Drug Targets Immune Response Manipulation: Recombinant Immunoreceptors Endow T-Cells with Predefined Specificity
Current Pharmaceutical Design Molecular Mechanism Behind the Synergistic Activity of Diphenylmethyl Selenocyanate and Cisplatin Against Murine Tumor Model
Anti-Cancer Agents in Medicinal Chemistry The Role of Flavonoids in Inhibiting IL-6 and Inflammatory Arthritis
Current Topics in Medicinal Chemistry